Observational study of dabigatran etexilate 150 mg in patients with moderate renal impairment undergoing elective total hip or knee replacement
- 1 July 2016
- journal article
- clinical trial
- Published by Elsevier in Thrombosis Research
- Vol. 143, 103-110
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Boehringer Ingelheim
- Bayer
- GlaxoSmithKline
This publication has 22 references indexed in Scilit:
- The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryExpert Review of Hematology, 2013
- Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groupsJournal of Thrombosis and Haemostasis, 2013
- Association of Mild to Moderate Chronic Kidney Disease With Venous ThromboembolismCirculation, 2012
- Prevention of VTE in Orthopedic Surgery PatientsChest, 2012
- Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practiceThrombosis and Haemostasis, 2012
- Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of ThrombinArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007
- Fatal pulmonary embolism in hospitalised patients: a necropsy reviewJournal of Clinical Pathology, 2004
- Economic Consequences of Venous Thromboembolism Following Major Orthopedic SurgeryAnnals of Pharmacotherapy, 2004